Bridging cancer biology and the patients' needs with nanotechnology-based approaches.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Cancer Treatment Reviews

• Publication date

  2014-06-01

• Fields of study

  Biology, Medicine, Materials Science, Engineering

• Identifiers
  DOI 10.1016/j.ctrv.2014.02.002PMID 24613464
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Polymer therapeutics-prospects for 21st century: the end of the beginning.

  2013cited by this paper
• Impact of anti-PLK1 siRNA-containing F3-targeted liposomes on the viability of both cancer and endothelial cells.

  2013cited by this paper
• Efficient intracellular delivery of siRNA with a safe multitargeted lipid-based nanoplatform.

  2013cited by this paper
• First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies

  2013cited by this paper
• Nanocarrier-Mediated Targeting of Tumor and Tumor Vascular Cells Improves Uptake and Penetration of Drugs into Neuroblastoma

  2013cited by this paper
• Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group.

  2013cited by this paper
• Challenging the future of siRNA therapeutics against cancer: the crucial role of nanotechnology

  2013cited by this paper
• The big picture on nanomedicine: the state of investigational and approved nanomedicine products.

  2013cited by this paper
• Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology.

  2013cited by this paper
• Cancer statistics, 2013

  2013cited by this paper
• Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts.

  2013cited by this paper
• Doxil®--the first FDA-approved nano-drug: lessons learned.

  2012cited by this paper
• Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile

  2012cited by this paper
• Targeting Strategies for Multifunctional Nanoparticles in Cancer Imaging and Therapy

  2012cited by this paper
• The hallmarks of cancer

  2012cited by this paper
• Targeted polymeric therapeutic nanoparticles: design, development and clinical translation.

  2012cited by this paper
• Nanomedicine: towards development of patient-friendly drug-delivery systems for oncological applications

  2012cited by this paper
• Targeted and intracellular triggered delivery of therapeutics to cancer cells and the tumor microenvironment: impact on the treatment of breast cancer

  2012cited by this paper
• HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity.

  2012cited by this paper
• Nanoparticle delivery of cancer drugs.

  2012influential reference
• Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.

  2012cited by this paper
• Toward a siRNA-containing nanoparticle targeted to breast cancer cells and the tumor microenvironment.

  2012cited by this paper
• Lyso-thermosensitive liposomal doxorubicin: an adjuvant to increase the cure rate of radiofrequency ablation in liver cancer.

  2011cited by this paper
• Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study.

  2011cited by this paper
• Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101.

  2011influential reference
• Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation.

  2011cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction

  2011cited by this paper
• Paclitaxel poliglumex for ovarian cancer

  2011cited by this paper
• Polymer therapeutics as nanomedicines: new perspectives.

  2011cited by this paper
• A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients

  2011cited by this paper
• Global cancer statistics

  2011cited by this paper
• Liposomal imatinib–mitoxantrone combination: Formulation development and therapeutic evaluation in an animal model of prostate cancer

  2011cited by this paper
• Albumin-Bound Paclitaxel: The Benefit of This New Formulation in the Treatment of Various Cancers

  2011cited by this paper
• Treating metastatic cancer with nanotechnology

  2011cited by this paper
• CRLX101 (formerly IT-101)–A Novel Nanopharmaceutical of Camptothecin in Clinical Development

  2011influential reference
• EPR effect based drug design and clinical outlook for enhanced cancer chemotherapy.

  2011cited by this paper
• First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.

  2011cited by this paper
• Nanomedicine(s) under the microscope.

  2011cited by this paper
• Polymeric Micelles in Anticancer Therapy: Targeting, Imaging and Triggered Release

  2010cited by this paper
• Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma.

  2010cited by this paper
• Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects.

  2010cited by this paper
• Surface Expressed Nucleolin Is Constantly Induced in Tumor Cells to Mediate Calcium-Dependent Ligand Internalization

  2010cited by this paper
• Development of HPMA copolymer-anticancer conjugates: clinical experience and lessons learnt.

  2009cited by this paper
• Impact of nanotechnology on drug delivery.

  2009cited by this paper
• In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy.

  2009cited by this paper
• Polymer therapeutics: clinical applications and challenges for development.

  2009cited by this paper
• Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet).

  2009cited by this paper
• Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia

  2009cited by this paper
• The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic.

  2009cited by this paper
• Drug ratio–dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo

  2009cited by this paper
• Poly (amino acid) micelle nanocarriers in preclinical and clinical studies.

  2008cited by this paper
• Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome.

  2008cited by this paper
• Nanocarriers as an emerging platform for cancer therapy.

  2007cited by this paper
• Sheddable Coatings for Long-Circulating Nanoparticles

  2007cited by this paper
• pH‐Sensitive liposomes‐principle and application in cancer therapy

  2007cited by this paper
• Liposomal daunorubicin as treatment for Kaposi’s sarcoma

  2007cited by this paper
• A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation

  2007cited by this paper
• Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome).

  2007cited by this paper
• Polymer therapeutics—polymers as drugs, drug and protein conjugates and gene delivery systems: Past, present and future opportunities*

  2006cited by this paper
• Polymer conjugates as anticancer nanomedicines

  2006cited by this paper
• Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy.

  2006cited by this paper
• Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential

  2006cited by this paper
• Cancer Statistics, 2006

  2006cited by this paper
• The emerging nanomedicine landscape

  2006cited by this paper
• Development of pH-sensitive liposomes that efficiently retain encapsulated doxorubicin (DXR) in blood.

  2006cited by this paper
• Polymer conjugates: nanosized medicines for treating cancer.

  2006cited by this paper
• Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia

  2006cited by this paper
• Albumin-bound paclitaxel: a next-generation taxane

  2006cited by this paper
• Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice

  2006influential reference
• Polymer conjugates for drug targeting. From inspired to inspiration!

  2006cited by this paper
• A Phase I and Pharmacokinetic Study of Paclitaxel Poliglumex (XYOTAX), Investigating Both 3-Weekly and 2-Weekly Schedules

  2005cited by this paper
• Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.

  2005cited by this paper
• Albumin-bound nanoparticle paclitaxel.

  2005cited by this paper
• Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.

  2004cited by this paper
• Antitumor effect of MCC‐465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts

  2004cited by this paper
• Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer.

  2004cited by this paper
• Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity

  2004influential reference
• On the formulation of pH-sensitive liposomes with long circulation times.

  2004cited by this paper
• The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta).

  2004cited by this paper
• Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin

  2004cited by this paper
• Phase I and Pharmacokinetic Study of Genexol-PM, a Cremophor-Free, Polymeric Micelle-Formulated Paclitaxel, in Patients with Advanced Malignancies

  2004cited by this paper
• A Phase I and Pharmacological Study of the Platinum Polymer AP5280 Given as an Intravenous Infusion Once Every 3 Weeks in Patients with Solid Tumors

  2004cited by this paper
• Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels

  2003cited by this paper
• Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer

  2003cited by this paper
• Ligand-targeted liposomal anticancer drugs.

  2003cited by this paper
• Poly-(L)-glutamic acid-paclitaxel (CT-2103) [XYOTAX], a biodegradable polymeric drug conjugate: characterization, preclinical pharmacology, and preliminary clinical data.

  2003cited by this paper
• Pegaspargase: a review of clinical studies.

  2003cited by this paper
• Effect of pegylation on pharmaceuticals

  2003cited by this paper
• Mechanisms of cancer drug resistance.

  2002cited by this paper
• Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma

  2002cited by this paper
• Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer.

  2002cited by this paper
• Chemistry and chemical biology of taxane anticancer agents.

  2001cited by this paper
• Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.

  2001cited by this paper
• Systemic p53 Gene Therapy of Cancer with Immunolipoplexes Targeted by Anti-Transferrin Receptor scFv

  2001cited by this paper
• The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors.

  2001cited by this paper
• Current status of pH-sensitive liposomes in drug delivery.

  2000cited by this paper
• A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model.

  2000cited by this paper
• Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.

  1999cited by this paper
• Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee.

  1999cited by this paper

• Bridging membrane fluidity studies with a predictive model of drug encapsulation to address industrial challenges of liposomal injectables manufacturing

  2025cites this paper
• Modelling the impact of nucleolin expression level on the activity of F3 peptide-targeted pH-sensitive pegylated liposomes containing doxorubicin

  2021cites this paper
• ISSN: 2525-8761

  2021cites this paper
• GMP-grade nanoparticle targeted to nucleolin downregulates tumor molecular signature, blocking growth and invasion, at low systemic exposure

  2021cites this paper
• Co-delivery of hydrophilic/hydrophobic drugs by multifunctional yolk-shell nanoparticles for hepatocellular carcinoma theranostics

  2020cites this paper
• Dextran-covered pH-sensitive oily core nanocapsules produced by interfacial Reversible Addition-Fragmentation chain transfer miniemulsion polymerization.

  2020cites this paper
• Recent Findings on Nanotechnology-based Therapeutic Strategies Against Hepatocellular Carcinoma.

  2019cites this paper
• Nanoliposome targeting in breast cancer is influenced by the tumor microenvironment.

  2019cites this paper
• Nanotherapy Targeting the Tumor Microenvironment.

  2019cites this paper
• Imaging modification of colon carcinoma cells exposed to lipid based nanovectors for drug delivery: a scanning electron microscopy investigation

  2019cites this paper
• Challenges facing nanotoxicology and nanomedicine due to cellular diversity.

  2018cites this paper
• Moving Liposome Technology from the Bench to the Oncological Patient: Towards Performance-by-Design

  2018cites this paper
• Particles and Nanoparticles in Pharmaceutical Products

  2018influential citation
• The effect of temperature on cadmium oxide (CdO) nanoparticles produced by synchrotron radiation in the human cancer cells, tissues and tumors

  2018cites this paper
• Vibrational biospectroscopic study and chemical structure analysis of unsaturated polyamides nanoparticles as anti–cancer polymeric nanomedicines using synchrotron radiation

  2018cites this paper
• Pet Imaging Of Early Therapeutic Response In Solid Tumors

  2017cites this paper
• Combination antitumor therapy with targeted dual‐nanomedicines☆

  2017cites this paper
• Structure-activity relationship study of Aib-containing amphipathic helical peptide-cyclic RGD conjugates as carriers for siRNA delivery.

  2017cites this paper
• CE method for the in‐process control of the synthesis of active substances conjugated with gold nanoparticles

  2017cites this paper
• Liposomal 64Cu-PET Imaging of Anti-VEGF Drug Effects on Liposomal Delivery to Colon Cancer Xenografts

  2017cites this paper
• Nanomaterials: promising structures for the management of oral cancer

  2017cites this paper
• Advances on nucleic acid delivery with nonviral vectors

  2017cites this paper
• Pros and Cons Controversy on Molecular Imaging and Dynamics of Double- Standard DNA/RNA of Human Preserving Stem Cells-Binding Nano Molecules with Androgens/Anabolic Steroids (AAS) or Testosterone Derivatives through Tracking of Helium-4 Nucleus (Alpha Particle) Using Synchrotron Radiation

  2017influential citation
• CCR9 in cancer: oncogenic role and therapeutic targeting

  2016cites this paper
• Engineering a Piperine Eluting Nanofibrous Patch for Cancer Treatment.

  2016cites this paper
• Design of cyclic RGD-conjugated Aib-containing amphipathic helical peptides for targeted delivery of small interfering RNA.

  2016cites this paper
• Magnetic nanoparticle-induced hyperthermia with appropriate payloads: Paul Ehrlich's "magic (nano)bullet" for cancer theranostics?

  2016cites this paper
• Unaprjeđenje antitumorske terapije primjenom nanotehnološkoga pristupa

  2016influential citation
• Size Matters: Developing Design Rules to Engineer Nanoparticles for Solid Tumour Targeting

  2015cites this paper
• DFT studies of 5-fluorouracil tautomers on a silicon graphene nanosheet

  2015cites this paper
• NCI investment in nanotechnology: achievements and challenges for the future.

  2015cites this paper
• Targeted intracellular delivery of synergistic drug combinations: tackling drug resistance in human breast cancer

  2015cites this paper
• Carbonic anhydrase XII is a new therapeutic target to overcome chemoresistance in cancer cells

  2015cites this paper
• Aberrant Signaling Pathways: Hallmark of Cancer Cells and Target for Nanotherapeutics

  2015cites this paper
• Nanomicellar Formulation of Clotrimazole Improves Its Antitumor Action toward Human Breast Cancer Cells

  2015cites this paper
• Microfluidics-assisted generation of stimuli-responsive hydrogels based on alginates incorporated with thermo-responsive and amphiphilic polymers as novel biomaterials.

  2015cites this paper
• Nucleolin overexpression in breast cancer cell sub-populations with different stem-like phenotype enables targeted intracellular delivery of synergistic drug combination.

  2015cites this paper
• Path-Breaking Directions of Nanotechnology-Based Chemotherapy and Molecular Cancer Therapy

  2015cites this paper
• Using the Electromagnetics of Cancer’s Centrosome Clusters to Attract Therapeutic Nanoparticles

  2015cites this paper
• Dual pH- and Temperature-Responsive Protein Nanoparticles.

  2015cites this paper
• Reduction-responsive polypeptide nanogel delivers antitumor drug for improved efficacy and safety.

  2015cites this paper
• Cationic fluorescent polymer core-shell nanoparticles for encapsulation, delivery, and non-invasively tracking the intracellular release of siRNA.

  2015cites this paper
• Functionalized Multiwalled Carbon Nanotubes as Carriers of Ruthenium Complexes to Antagonize Cancer Multidrug Resistance and Radioresistance.

  2015cites this paper
• Nanotechnology and additive manufacturing platforms for clinical medicine: An investigation of 3D printing bioactive constructs and halloysite nanotubes for drug delivery and biomaterials

  2014cites this paper
• Molecular dynamics simulations of drug delivery liposomes and their interactions with bloodstream elements

  2014cites this paper
• In Vivo Bacteriophage Peptide Display to Tailor Pharmacokinetics of Biological Nanoparticles

  2014cites this paper
• Periostin in intrahepatic cholangiocarcinoma: pathobiological insights and clinical implications.

  2014cites this paper